Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting

Published:2022-05-01 Issue:5 Volume:8 Page:698
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Pivot Xavier¹,Georgievich M. A.²,Shamrai Volodymyr³,Dzagnidze Giorgi⁴,Soo Hoo Hwoei Fen⁵,Kaewkangsadan Viriya⁶,Petrelli Fausto⁷,Villanueva Cristian⁸,Nikolaevich Lipatov O.⁹,Hii Jocelyn¹⁰,Kim Jamie¹⁰,Pradhan Sumita¹⁰,Jaison Litha¹⁰,Feyaerts Peggy¹⁰,Kaufman Leonard¹¹,Derde Marie-Paule¹¹,Bonamy Ghislain M. C.¹⁰,Deforce Filip¹¹,Cox David G.¹

Affiliation:

1. Institute of Cancer Strasbourg, Strasbourg, France

2. St Petersburg GBUZ City Clinical Oncology Dispensary, St Petersburg, Russia

3. Vinnytsia Regional Clinical Oncological Dispensary, Vinnytsia, Ukraine

4. S. Khechinashvili University Hospital, Tbilisi, Georgia

5. Penang General Hospital, Penang Island, Malaysia

6. Department of Surgery, Phramongkutklao hospital, Bangkok, Thailand

7. Oncology Unit, ASST Bergamo Ovest, Trevigilio, Bergamo, Italy

8. Clinique Clementville, Montpellier, Montpellier, France

9. Republican Clinical Oncology Dispensary of Ministry of Health Bashkortostan Republic, Republic of Russia

10. Prestige BioPharma Ltd, Singapore

11. DICE, Naamloze vennootschap, Belgium

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2789767/jamaoncology_pivot_2022_oi_210110_1652478713.73338.pdf

Reference17 articles.

1. A randomized phase I study comparing the pharmacokinetics of HD201, a trastuzumab biosimilar, with European Union-sourced Herceptin.;Pivot;Clin Ther,2018

2. TROIKA-1: a double-blind, randomized, parallel group study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin® and US-Herceptin® in healthy male subjects.;Demarchi;Pharmacol Res Perspect,2021

3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.;Gianni;Lancet,2010

4. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.;Buzdar;J Clin Oncol,2005

5. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.;Untch;J Clin Oncol,2010

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequently Together, Among Model Systems Molecular Alterations: Cancer Maintenance Markers with Translational Study Design;2024-01-30

2. Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs;International Journal of Molecular Sciences;2024-01-05

3. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China;JAMA Network Open;2023-10-12

4. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis;European Journal of Cancer;2023-09

5. Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting;BMC Cancer;2023-01-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3